Azcad Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 08-07-2024
- Paid Up Capital ₹ 2.25 M
as on 08-07-2024
- Company Age 10 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.53 M
as on 08-07-2024
- Revenue 23.11%
(FY 2022)
- Profit 3.32%
(FY 2022)
- Ebitda 17.66%
(FY 2022)
- Net Worth 35.78%
(FY 2022)
- Total Assets 25.30%
(FY 2022)
About Azcad Pharmaceuticals
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.25 M.
The company currently has active open charges totaling ₹6.53 M.
Usha Magesh, Magesh Krishnamoorthy, Kannappanhari Krishnan, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232TN2014PTC097172
- Company No.
097172
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Sep 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Azcad Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Usha Magesh  | Director | 30-Sep-2022 | Current |
| Magesh Krishnamoorthy | Director | 02-Sep-2014 | Current |
| Kannappanhari Krishnan | Director | 02-Sep-2014 | Current |
| Mohana Harikrishnan | Director | 30-Sep-2022 | Current |
Financial Performance of Azcad Pharmaceuticals.
Azcad Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.11% increase. The company also saw a slight improvement in profitability, with a 3.32% increase in profit. The company's net worth Soared by an impressive increase of 35.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Azcad Pharmaceuticals?
In 2021, Azcad Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Tamilnad Mercantile Bank Limited Creation Date: 13 Jan 2022 | ₹0.18 M | Open |
Hdfc Bank Limited Creation Date: 30 Apr 2021 | ₹1.35 M | Open |
Tamilnad Mercantile Bank Limited Creation Date: 28 Sep 2016 | ₹5.00 M | Open |
How Many Employees Work at Azcad Pharmaceuticals?
Unlock and access historical data on people associated with Azcad Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Azcad Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Azcad Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
